These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 32522920

  • 1. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R, Kameda T, Nakashima S, Shimada H, Fahmy Mansour MM, Kato M, Miyagi T, Kadowaki N, Dobashi H.
    Intern Med; 2020 Sep 01; 59(17):2105-2112. PubMed ID: 32522920
    [Abstract] [Full Text] [Related]

  • 2. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
    Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.
    Intern Med; 2019 May 01; 58(9):1257-1262. PubMed ID: 30626831
    [Abstract] [Full Text] [Related]

  • 3. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
    Wakiya R, Kameda T, Ueeda K, Nakashima S, Shimada H, Mansour MF, Kato M, Miyagi T, Miyatake N, Kadowaki N, Dobashi H.
    Lupus; 2019 Jun 01; 28(7):826-833. PubMed ID: 31068068
    [Abstract] [Full Text] [Related]

  • 4. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y, Oiwa H.
    Intern Med; 2020 Oct 15; 59(20):2485-2490. PubMed ID: 32641656
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
    Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Inoue Y, Ueno M, Tanaka Y.
    Int J Rheum Dis; 2019 Mar 15; 22(3):434-442. PubMed ID: 30338639
    [Abstract] [Full Text] [Related]

  • 6. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ.
    Arthritis Care Res (Hoboken); 2016 Sep 15; 68(9):1295-302. PubMed ID: 26749299
    [Abstract] [Full Text] [Related]

  • 7. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E, Yokogawa N, Shimada K, Sugii S.
    Lupus; 2019 Oct 15; 28(12):1473-1476. PubMed ID: 31575325
    [Abstract] [Full Text] [Related]

  • 8. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Inoue Y, Ueno M, Ohkubo N, Fujita Y, Tanaka Y.
    Int J Rheum Dis; 2020 Apr 15; 23(4):549-558. PubMed ID: 32020727
    [Abstract] [Full Text] [Related]

  • 9. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I, Medina-Cintrón N, Arroyo-Ávila M, González-Sepúlveda L, Vilá LM.
    Lupus Sci Med; 2020 May 15; 7(1):. PubMed ID: 32434863
    [Abstract] [Full Text] [Related]

  • 10. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N, Kato Y, Sugii S, Inada S.
    Mod Rheumatol; 2012 Apr 15; 22(2):249-55. PubMed ID: 21842436
    [Abstract] [Full Text] [Related]

  • 11. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
    Monzavi SM, Alirezaei A, Shariati-Sarabi Z, Tavakol Afshari J, Mahmoudi M, Dormanesh B, Jahandoost F, Khoshdel AR, Etemad Rezaie A.
    Inflammopharmacology; 2018 Oct 15; 26(5):1175-1182. PubMed ID: 29987550
    [Abstract] [Full Text] [Related]

  • 12. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
    Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.
    Clin Rheumatol; 2019 Oct 15; 38(10):2785-2791. PubMed ID: 31175481
    [Abstract] [Full Text] [Related]

  • 13. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Boutin du LT, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Jallouli M, Leroux G, Cohen-Bittan J, Tanguy ML, Hulot JS, Lechat P, Musset L, Amoura Z, Piette JC, Group PLUS.
    Ann Rheum Dis; 2013 Nov 15; 72(11):1786-92. PubMed ID: 23144449
    [Abstract] [Full Text] [Related]

  • 14. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
    Yoshida M, Minowa K, Amano H, Asai Y, Yamaji K, Tamura N.
    Lupus; 2021 Aug 15; 30(9):1378-1384. PubMed ID: 33966540
    [Abstract] [Full Text] [Related]

  • 15. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C, Moroni G.
    Expert Opin Drug Saf; 2017 Mar 15; 16(3):411-419. PubMed ID: 27927040
    [Abstract] [Full Text] [Related]

  • 16. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
    Yeon Lee J, Lee J, Ki Kwok S, Hyeon Ju J, Su Park K, Park SH.
    Arthritis Care Res (Hoboken); 2017 Apr 15; 69(4):536-542. PubMed ID: 27390146
    [Abstract] [Full Text] [Related]

  • 17. Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
    Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.
    Int J Rheum Dis; 2019 Mar 15; 22(3):468-472. PubMed ID: 30406967
    [Abstract] [Full Text] [Related]

  • 18. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
    Wakiya R, Ueeda K, Shimada H, Nakashima S, Kameda T, Miyatake N, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi H.
    Clin Rheumatol; 2022 Nov 15; 41(11):3345-3353. PubMed ID: 35849246
    [Abstract] [Full Text] [Related]

  • 19. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N, Tanikawa A, Amagai M, Kato Y, Momose Y, Arai S, Eto H, Ikeda T, Furukawa F.
    Mod Rheumatol; 2013 Mar 15; 23(2):318-22. PubMed ID: 22581095
    [Abstract] [Full Text] [Related]

  • 20. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L, Perel-Winkler A, Miceli J, Neville K, Danias G, Nguyen S, Dervieux T, Kapoor T, Giles J, Askanase A.
    Lupus; 2019 Jun 15; 28(7):862-867. PubMed ID: 31122136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.